Lipid lowering therapy (LLT) with statins have the strongest evidence regarding the reduction in cardiovascular (CV) events and total mortality and thus are the cornerstone of every global guideline after lifestyle. Despite this evidence there is a gap between current treatment uptake and clinical guidelines including a failure to achieve cholesterol targets in patients. We think that there are 3 main factors contributing in this difference. The first is the relative effectiveness of the available LLT, and statin intolerance and the use of alternative drugs to statins (1) . The second are patient related factors and recently, considerable emphasis has been placed on improving patient compliance, in light of the extremely disappointing persistence to statin therapy. The third important factor which needs considerable attention is the view of health care professionals towards LLT and whether uncertainties in particular about the use of more potent statin regimes still persist and thus limit effective utilisation of LLT. Among the statins used rosuvastatin and atorvastatin dominate and these potent statins are being used with increasing frequency (2,3).
More recently the annual decline in achieved LDL-C levels has plateaued. The background is unclear but includes factors such as: the reluctance of doctors to increase the statin dose; reluctance to switch to more potent statins; reluctance to initiate combination therapy when their patients do not reach target levels; or a lack of awareness of the benefits of further reductions in LDL-C in high risk groups.
The CEPHEUS study (Centralized Pan-European survey on the under-treatment of hypercholesterolaemia) has shown that failure to achieve lipid goals do not trigger further modification of LLT (4) . Doubling the statin dose or changing to a more potent statin are potential options when lipid goals are not reached but the gain may be modest. For instance doubling the dose of current statin, results in a further 6% LDL-C decrease (rule of six) (5).
In the Hungarian MULTI GAP study the plateau in the LDL-C decrease was observed despite the more frequent use of the most potent statins. In a retrospective database analysis using atorvastatin monotherapy less than half of patients achieved their goals (6) . In a study based on rosuvastatin administration, in clinical trials rather than real world data, the 2.5 mmol/l LDL-C goal attainment was under 60%, and less than 20% of patients achieved the very high risk goal of 1.8 mmoL/l (7). In EUROASPIRE IV the LDL-C goal of 2.5 mmol/l was achieved by half of the patients, the 1.8 mmol/l by less than 30% (8).
The results of IMPROVE-IT support the "lower the better" concept and have proven that a non-statin drug which lowers LDL-C is able for significantly reducing the number of vascular events (9) . These results provide us with evidence based data for the statin-ezetimibe combination.
J U S T A C C E P T E D

Achieving lipid goals at the first attempt
In order to improve compliance, the continuous education of patients is important. Also continuous emphasis on improving the doctors' knowledge about LLTs as data emerges is essential. Even with further education intensification of statin therapy may not offer much more incremental reduction in LDL-C thus ESC/EAS targets may not be attained as doubling statin dose only results in a further 6% reduction in LDL-C.
The 'old fashioned' LLT starts with a low dose statin and is based on titration of the dose.
Since the titration often is omitted, in this type of approach initiating LLT without uptitration is believed to be one of the obvious causes of failing to achieve the target levels. Contrary to this traditional approach the ESC/EAS guidelines recommend defining the desired percentage LDL-C lowering required to achieve LDL-C goals and to start an appropriate therapy in one step (10). This could be a useful approach but requires that the physician calculate the expected percentage reduction and the best approach at the outset. This is ideal for statin naïve patients and the guidelines do not give a clear recommendation for cases already receiving LLT.
The combination of ezetimibe could be useful, to help target goal attainment and thus result in reduction of risk. Masana et al have tried to simplify the ESC/EAS guidelines by providing scenarios when statins suffice or when combination therapy is desirable based on baseline LDL-C and baseline risk (11). This approach could be ideal in statin naive patients where the desired and expected effect is predictable. The drawback of this approach, again, the lack a consideration of former LLT in patients already receiving statins.
We propose an algorithm to guide physicians when faced with patients not at goal who statin naïve or are already receiving LLT. Table 1A starting LDL-C levels. Here we have included the fenofibrate which is primarily used in combination with statins in cases with high triglyceride and/or low HDL-cholesterol for the reduction of residual lipid risk, but its 10% LDL-C reduction is modest in effect but these mediacations are relatively inexpensive in contrast to more potent but expensive Proprotein convertase subtilisin-like kexin type 9 inhibitors (PCSK9i). The administration of nutraceuticals is acceptable in any level of risk to "help" statins' LDL-C lowering effect, and could be considered as inexpensive though less potent options before PCSK9i-s. The fenofibrate and nutraceuticals should be considered mainly in younger patients with very high LDL-C levels and in primary prevention cases. This table can be used to classify the current therapy of patients already on LLT and for choosing the appropriate therapy after the determination of the desired level for change. 
